» Articles » PMID: 1320015

Mechanisms by Which Lipoprotein Lipase Alters Cellular Metabolism of Lipoprotein(a), Low Density Lipoprotein, and Nascent Lipoproteins. Roles for Low Density Lipoprotein Receptors and Heparan Sulfate Proteoglycans

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1992 Jul 5
PMID 1320015
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

We sought to investigate effects of lipoprotein lipase (LpL) on cellular catabolism of lipoproteins rich in apolipoprotein B-100. LpL increased cellular degradation of lipoprotein(a) (Lp(a)) and low density lipoprotein (LDL) by 277% +/- 3.8% and 32.5% +/- 4.1%, respectively, and cell association by 509% +/- 8.7% and 83.9% +/- 4.0%. The enhanced degradation was entirely lysosomal. Enhanced degradation of Lp(a) had at least two components, one LDL receptor-dependent and unaffected by heparitinase digestion of the cells, and the other LDL receptor-independent and heparitinase-sensitive. The effect of LpL on LDL degradation was entirely LDL receptor-independent, heparitinase-sensitive, and essentially absent from mutant Chinese hamster ovary cells that lack cell surface heparan sulfate proteoglycans. Enhanced cell association of Lp(a) and LDL was largely LDL receptor-independent and heparitinase-sensitive. The ability of LpL to reduce net secretion of apolipoprotein B-100 by HepG2 cells by enhancing cellular reuptake of nascent lipoproteins was also LDL receptor-independent and heparitinase-sensitive. None of these effects on Lp(a), LDL, or nascent lipoproteins required LpL enzymatic activity. We conclude that LpL promotes binding of apolipoprotein B-100-rich lipoproteins to cell surface heparan sulfate proteoglycans. LpL also enhanced the otherwise weak binding of Lp(a) to LDL receptors. The heparan sulfate proteoglycan pathway represents a novel catabolic mechanism that may allow substantial cellular and interstitial accumulation of cholesteryl ester-rich lipoproteins, independent of feedback inhibition by cellular sterol content.

Citing Articles

The association between a genetic variant in the gene, metabolic parameters and vascular disease in patients at high cardiovascular risk.

Heidemann B, Visseren F, van Setten J, Marais A, Koopal C Cardiovasc Endocrinol Metab. 2023; 12(1):e0278.

PMID: 36699192 PMC: 9870215. DOI: 10.1097/XCE.0000000000000278.


Lipoprotein Lipase Up-regulation in Hepatic Stellate Cells Exacerbates Liver Fibrosis in Nonalcoholic Steatohepatitis in Mice.

Teratani T, Tomita K, Furuhashi H, Sugihara N, Higashiyama M, Nishikawa M Hepatol Commun. 2019; 3(8):1098-1112.

PMID: 31388630 PMC: 6671781. DOI: 10.1002/hep4.1383.


Triglyceride-rich lipoprotein binding and uptake by heparan sulfate proteoglycan receptors in a CRISPR/Cas9 library of Hep3B mutants.

Anower-E-Khuda F, Singh G, Deng Y, Gordts P, Esko J Glycobiology. 2019; 29(8):582-592.

PMID: 31094413 PMC: 6639542. DOI: 10.1093/glycob/cwz037.


Suppression of Hepatic FLOT1 (Flotillin-1) by Type 2 Diabetes Mellitus Impairs the Disposal of Remnant Lipoproteins via Syndecan-1.

Chen K, Wu Q, Hu K, Yang C, Wu X, Cheung P Arterioscler Thromb Vasc Biol. 2017; 38(1):102-113.

PMID: 29162604 PMC: 5982506. DOI: 10.1161/ATVBAHA.117.310358.


Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials.

Sahebkar A, Simental-Mendia L, Watts G, Serban M, Banach M BMC Med. 2017; 15(1):22.

PMID: 28153024 PMC: 5290642. DOI: 10.1186/s12916-017-0787-7.